HomeTrialNCT07290257
🔬NCT07290257Phase 4RECRUITING

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)

Study Summary

The key objectives of this low-intervention clinical study are to evaluate tolerability, long-term safety and long-term efficacy for patients with Alagille syndrome (ALGS) who are prescribed Livmarli.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment100 participants
Primary Completion
Lead SponsorMirum Pharmaceuticals, Inc.
Data Retrieved2026-04-11 04:21:18.704594+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.